Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | ACACA | Q13085 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | OXTR | P30559 | 1/20 | 0.37 |
| ▸ | GPR183 | P32249 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.35 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4843911 | 0.91 | F10 (0.48) | F10HRH3L3MBTL3L3MBTL1ACHE | |
| SCHEMBL6215250 | 0.87 | F10 (0.48) | F10HRH3L3MBTL3L3MBTL1ACHE | |
| SCHEMBL3000428 | 0.85 | F10 (0.58) | F10ACACBACACAL3MBTL3L3MBTL1 | |
| Hydrochloric Acid SCHEMBL4840239 | 0.84 | F10 (0.57) | F10ACACBACACAL3MBTL3L3MBTL1 | |
| Hydrochloric Acid SCHEMBL4841878 | 0.84 | F10 (0.57) | F10ACACBACACAL3MBTL3L3MBTL1 | |
| SCHEMBL5496127 | 0.83 | SMN1; SMN2 (0.47) | L3MBTL3L3MBTL1ACHECYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL4840285 | 0.82 | F10 (0.39) | F10ACACBACACAHRH3L3MBTL3 | |
| SCHEMBL6215912 | 0.82 | F10 (0.53) | F10ACACBACACAL3MBTL3L3MBTL1 | |
| Fumaric Acid SCHEMBL4840016 | 0.82 | F10 (0.54) | F10ACACBACACAL3MBTL3L3MBTL1 | |
| Hydrochloric Acid SCHEMBL4844439 | 0.81 | CACNA2D1 (0.46) | F10HRH3ACHEGPR183ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351822-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2008-04-01 | — | — | US | disclosed |
| US-6946467-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-09-20 | — | — | US | disclosed |
| US-6936611-B2 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| EP-1510515-A1 | Phenylglycine derivatives as serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-03-02 | — | — | EP | disclosed |
| US-6855715-B1 | Serine protease inhibitors | ELI LILLY AND COMPANY (US) | 2005-02-15 | — | — | US | disclosed |
| US-20050032790-A1 | For example, 1-(2-Amino-4-chlorobenzoyl-D-phenylglycinyl)-4,4'-bispiperidine; for treatment of thrombosis, emphysema, cirrhosis; antiarthritic agents, anticancer agents, antihistamines | LIEBESCHUETZ JOHN WALTER (GB) | 2005-02-10 | — | — | US | disclosed |
| US-20040176363-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-09-09 | — | — | US | disclosed |
| EP-1289972-B1 | SERINE PROTEASE INHIBITORS | LILLY CO ELI (US) | 2004-09-08 | — | — | EP | disclosed |
| US-20040142963-A1 | Serine protease inhibitors | LIEBESCHUETZ JOHN WALTER (GB) | 2004-07-22 | — | — | US | disclosed |
| US-20030055246-A1 | Serine protease inhibitors | PROTHERICS MOLECULAR DESIGN LIMITED (GB) | 2003-03-20 | — | — | US | disclosed |
| EP-1289972-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096323-A1 | SERINE PROTEASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055246-A1 | Serine protease inhibitors | CTRL, CPN1, LOXL1 | F10 992/4885ACACB 2508/4885ACACA 1372/4885 |
| US-20050032790-A1 | For example, 1-(2-Amino-4-chlorobenzoyl-D-phenylglycinyl)-4,4'-bispiperidine; for treatment of thrombosis, emphysema, cirrhosis; antiarthritic agents, anticancer agents, antihistamines | SERPINB1, SERPINE1, SERPINH1 | F10 219/4885ACACB 1761/4885ACACA 1806/4885 |
| US-20040142963-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | F10 60/4885ACACB 2492/4885ACACA 1789/4885 |
| US-20040176363-A1 | Serine protease inhibitors | SERPINE1, PRSS1, SERPINB1 | F10 60/4885ACACB 2492/4885ACACA 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.